Pfizer Inc. $PFE Stock Holdings Increased by Richardson Financial Services Inc.

Richardson Financial Services Inc. grew its position in Pfizer Inc. (NYSE:PFE) by 14.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,762 shares of the biopharmaceutical company’s stock after acquiring an additional 605 shares during the quarter. Richardson Financial Services Inc.’s holdings in Pfizer were worth $119,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. GKV Capital Management Co. Inc. bought a new position in Pfizer in the 1st quarter valued at about $27,000. North Capital Inc. bought a new position in shares of Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd bought a new position in shares of Pfizer in the first quarter valued at approximately $28,000. Horizon Financial Services LLC bought a new position in shares of Pfizer in the first quarter valued at approximately $35,000. Finally, WPG Advisers LLC bought a new position in shares of Pfizer in the first quarter valued at approximately $35,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 1.7%

NYSE:PFE opened at $24.81 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.82. The firm has a market capitalization of $141.03 billion, a price-to-earnings ratio of 13.19, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. The stock has a fifty day simple moving average of $24.86 and a 200 day simple moving average of $24.13.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the company posted $0.60 EPS. Pfizer’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on PFE shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday. Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Morgan Stanley reduced their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday. Finally, Bank of America raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.35.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.